TECH - Bio-Techne Corporation

TECH

$71.23 0.13 (-0.18%) Last updated: Jul 15, 2026 02:23

52-Week Range

$71.23

$43.20 $71.23 $72.16

Fundamentals Overview

Bio-Techne Corporation is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 102 P/B 5.33 P/S 9.21

Intrinsic value (DCF)

-67.4% downside vs price

Profitability

Net margin 9%

Risk (Beta)

1.29 — higher vol

Earnings & growth

EPS $0.70 Rev +5.3% Profit +34.3% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 53% confidence Risk: High Volatility — Beta 1.29. Consider smaller position size due to higher beta.

Supporting (Buy):

Analyst grade: B · 3M vs S&P 500: +14.2% · 3M vs Healthcare sector: +16.8%

Pressures (Sell):

DCF 67.4% downside vs price · Sentiment weakening (7 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$11.15B

P/E (TTM)

102.02

EPS (TTM)

$0.70

Dividend Yield

0.45%

52-Week Range

$43.20 - $72.16

Volume vs Avg

N/A

Beta

1.29

About

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth f...

Sector: Healthcare

Headquarters: US

Employees: 3,100

IPO Date: Feb 1989

Website: www.bio-techne.com

Beta: 1.29 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 11, Equal Weight: 1, Hold: 3, In Line: 4, Market Perform: 1, Neutral: 2, Outperform: 2, Overweight: 3, Sector Outperform: 1, Sector Perform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $23.24; current price is $71.23. That’s a -67.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric	Value
Valuation
P/E (TTM)	102.02
DCF value (model)	$23.24 (-67.4% vs price)
PEG (TTM)	N/A
P/B (TTM)	5.33
P/S (TTM)	9.21
P/FCF (TTM)	41.37
Liquidity & enterprise
Current Ratio (TTM)	4.49
Quick Ratio (TTM)	3.18
Cash Ratio (TTM)	1.37
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	9.05%
Gross margin (TTM)	64.96%
Operating margin (TTM)	12.7%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for TECH.

Analyst Sentiment at a Glance

B Sentiment Weakening

Buy 11Equal Weight 1Hold 3In Line 4Market Perform 1Neutral 2Outperform 2Overweight 3Sector Outperform 1Sector Perform 2

2 upgrades, 7 downgrades

Price Target Consensus

Current $71.23

Median $73.00

Consensus $66.44

Low consensus $50.00

High consensus $79.00

Stock Grades (Institutions)

Institution	Action	Previous Grade	New Grade	Date
RBC Capital	downgrade	Outperform	Sector Perform	2026-07-09
TD Cowen	downgrade	Buy	Hold	2026-06-30
Benchmark	downgrade	Buy	Hold	2026-06-30
Citigroup	downgrade	Buy	Neutral	2026-06-29
Stephens & Co.	downgrade	Overweight	Equal Weight	2026-06-26
Baird	maintain	Neutral	Neutral	2026-06-26
William Blair	downgrade	Outperform	Market Perform	2026-06-26
Citigroup	maintain	Buy	Buy	2026-05-07
Evercore ISI Group	maintain	In Line	In Line	2026-05-07
Wells Fargo	maintain	Overweight	Overweight	2026-05-07
Evercore ISI Group	maintain	In Line	In Line	2026-04-06
Wells Fargo	maintain	Overweight	Overweight	2026-02-06
TD Cowen	maintain	Buy	Buy	2026-02-05
Stifel	maintain	Hold	Hold	2026-02-05
Evercore ISI Group	maintain	In Line	In Line	2026-02-05
UBS	maintain	Buy	Buy	2026-02-05
Citigroup	maintain	Buy	Buy	2026-02-05
Evercore ISI Group	downgrade	Outperform	In Line	2026-01-05
Argus Research	maintain	Buy	Buy	2025-11-20
UBS	maintain	Buy	Buy	2025-11-06
Wells Fargo	maintain	Overweight	Overweight	2025-11-06
TD Cowen	maintain	Buy	Buy	2025-10-14
Evercore ISI Group	maintain	Outperform	Outperform	2025-10-07
RBC Capital	upgrade	Sector Perform	Outperform	2025-09-03
Citigroup	upgrade	Neutral	Buy	2025-08-21
RBC Capital	maintain	Sector Perform	Sector Perform	2025-08-07
Scotiabank	maintain	Sector Outperform	Sector Outperform	2025-07-11
Benchmark	maintain	Buy	Buy	2025-06-05
UBS	maintain	Buy	Buy	2025-05-09
Benchmark	maintain	Buy	Buy	2025-05-08